Ischemic Heart Disease

Targeted Transthoracic Acoustic Activation of Systemically Administered Nanodroplets to Detect Myocardial Perfusion Abnormalities

Thomas R. Porter, MD; Christopher Arena, PhD; Samer Sayyed, MD; John Lof, MS; Robin R. High, MBA, MA, MM; Feng Xie, MD; Paul A. Dayton, PhD

Background—Liquid core nanodroplets containing condensed gaseous fluorocarbons can be vaporized at clinically relevant acoustic energies and have been hypothesized as an alternative ultrasound contrast agent instead of gas-core agents. The potential for targeted activation and imaging of these agents was tested with droplets formulated from liquid octafluoropropane (C3) and 1:1 mixtures of C3 with liquid decafluorobutane (C3C4).

Methods and Results—In 8 pigs with recent myocardial infarction and variable degrees of reperfusion, transthoracic acoustic activation was attempted using 1.3 to 1.7 MHz low (0.2 mechanical index [MI]) or high MI (1.2 MI) imaging in real time (32–64 Hertz) or triggered 1:1 at end systole during a 20% C3 or C3C4 droplet infusion. Any perfusion defects observed were measured and correlated with delayed enhancement magnetic resonance imaging and postmortem staining. No myocardial contrast was produced with any imaging setting when using C3C4 droplets or C3 droplets during low MI real-time imaging. However, myocardial contrast was observed in all 8 pigs with C3 droplets when using triggered high MI imaging and in 5 of 6 pigs that had 1.7 MHz real-time high MI imaging. Although quantitative myocardial contrast was lower with real-time high MI imaging than 1:1 triggering, the correlation between real-time resting defect size and infarct size was good (r=0.97; P<0.001), as was the correlation with number of transmural infarcted segments by delayed enhancement imaging.

Conclusions—Targeted transthoracic acoustic activation of infused intravenous C3 nanodroplets is effective, resulting in echogenic and persistent microbubbles which provide real-time high MI visualization of perfusion defects. (Circ Cardiovasc Imaging. 2016;9:e003770. DOI: 10.1161/CIRCIMAGING.115.003770.)

Key Words: acoustic activation ■ angiography ■ echocardiography ■ fluorocarbons ■ perfusion

Perfluorocarbon gases have improved the ability of microbubbles to serve as left ventricular diagnostic contrast agents. Their high molecular weight and reduced solubility have resulted in improved microbubble persistence after venous injection, permitting consistent left ventricular opacification and myocardial contrast.1,2 However, by the time microbubbles reach the systemic circulation from a venous injection, they are susceptible to ultrasound-induced destruction. Although this has been exploited successfully to better quantify myocardial perfusion,3,4 it has prevented the real-time visualization of myocardial contrast at power outputs that could improve image quality and reduce attenuation. One reason for the fragility of intravenously infused microbubbles is their reduced size on reaching the systemic circulation, whereas larger intra-arterially injected microbubbles are more resistant to ultrasound destruction.5

Both octafluoropropane (C3) and decafluorobutane gases can be condensed under pressure to their liquid phases within lipid shells to submicron size droplets.6,7 These same droplets can be vaporized by ultrasound to reform acoustically active microbubbles at transducer-targeted locations.8,9 The nanodroplets formulated from these low–boiling point perfluorocarbons require less acoustic pressure than those from higher boiling point perfluorocarbons, and purely C3 droplets have vaporized at peak negative pressures that are achievable with current commercially available transthoracic ultrasound systems.8,9 The microbubbles produced are ≈5× the size of the original droplet.7 Despite extensive in vitro studies, the acoustic properties of these created microbubbles within the myocardial microcirculation are unknown. The purpose of this article was to test whether acoustic activation of condensed low–boiling point droplets was possible with commercially...
Acoustic Droplet Preparation and Characterization

C3 and 1:1 mixtures of octafluoropropane/decafluorobutane (C3C4) were formed by condensing seed microbubbles using previously established techniques. Briefly, to generate microbubbles, the headspace within stock vials of lipid solution was gas-exchanged with either C3 or C3C4 and subject to standard agitation (Vialmix, Bristol-Myers-Squibb, New York, NY). Individual microbubble vials were then immersed in an isopropanol bath maintained at −10°C and exposed to a gradual increase in external pressure using an adjustable air source until condensation was observed. The droplets were stable and appeared as a clear solution during infusion (Figure 1).

The sizes of the condensed droplets were polydisperse. As such, 2 separate sizing systems were required to characterize the entire range of droplet sizes. The NanoSight NS500 (Malvern Instruments Inc., Westborough, MA) was used to capture droplet content ranging from 50 to 1000 nm in diameter, and the AccuSizer 780A (Particle Sizing Systems, Port Richey, FL) was used to capture droplet content ranging from 500 to 50,000 nm in diameter. According to the NanoSight system, the average distribution (3 separate vials) of C3 droplets had a mode size of 109.1±6.8 nm and a total concentration of 2.8×1011±1.3×1011 particles/mL, whereas C3C4 droplets had a mode size of 125.9±3.6 nm and a total concentration of 1.6×1011±8.8×1010. The differences in size and concentration between C3 and C3C4 droplets are expected based on ideal gas laws and the concentration of seed microbubbles. According to the AccuSizer, the average distribution (3 separate vials) of C3 droplets had a mode size of 623.3±37.9 nm and a total concentration of 2.6×108±3.3×107 particles/mL, whereas C3C4 droplets had a mode size of 610.0±10.0 nm and a total concentration of 3.2×108±3.5×107. It is important to note that although the concentration of larger droplet content reported by the AccuSizer is 3 orders of magnitude larger than that reported by the NanoSight, it is likely that this larger droplet content is primarily responsible for contrast enhancement.

Animal Studies

All studies performed were approved by the Institutional Animal Care and Use Committee at the University of Nebraska Medical Center. Eight pigs (mean weight 64±6 kg) that were 48 hours post an acute ST-segment-elevation myocardial infarction were studied. One additional pig without infarction was used to demonstrate the effect of mechanical index (MI) on activation threshold in real time and the washout of activated droplets from the myocardium and left ventricular cavity. The infarction was created using an established protocol that involves balloon injury of the mid left anterior descending artery followed by a 50 day 15% lard diet. At 50 days, the left anterior descending was balloon-injured again in the same location, after which the balloon was inflated slowly proximal to the injury site to create stasis, and small 0.2 to 0.3 mL aliquots of thrombosing venous blood were reinjected through the balloon catheter until a sustained (20 min) angiographic occlusion was achieved. Pigs were then treated with intermittent high MI impulses (1.0 MI) from a modified low-frequency diagnostic and therapeutic transducer (900 kHz GE Vivid E9; GE Global Research) during a 30 min intravenous microbubble infusion (3% definity). All pigs received 300 mg of aspirin and 600 mg of clopidogrel via a nasogastric tube combined with a heparin infusion for 60 min. Using this protocol, epicardial recanalization occurred in 5 of the 8 pigs by 90 min into therapy. After the myocardial infarction and ultrasound treatment, all pigs were allowed to recover and placed back on a regular diet for 2 days.

At 48 hours post infarction, the pigs underwent cardiac magnetic resonance examinations (described below) to define infarct size. After this, pigs underwent 20% intravenous infusions (diluted in normal saline) of C3 or 20% infusion of the 1:1 ratio of C3C4 droplets. Imaging was initiated at 1 min after the infusion was started. Each infusion was separated from the other by 5 to 7 min to allow clearance of the previous droplets from the system, which was verified by ultrasound imaging. Before and during all infusions, arterial blood pressure, heart rate, and oxygen saturation monitoring were recorded.

Ultrasound Activation Protocols

Using a Philips S5-1 transducer (Philips Healthcare), a triggered harmonic high MI at 1.3 MHz (1.1 MI) was tested using mid and distal short axis imaging of the left ventricle. At the 1.3 MHz harmonic setting, the images were triggered to end systole at either one frame every 1 cardiac cycle or every 4 cardiac cycles. We also tested 2 real-time settings: a 20-Hz frame rate low MI (0.2–0.25) setting (Power Modulation) traditionally used for microbubble imaging at 1.7 MHz, and a high MI (1.2 MI) real-time setting of 1.7 MHz harmonic imaging. The purpose of the high MI real-time setting was to determine whether droplets within the microcirculation could be activated and still visualized without destruction. To further evaluate this in 3 of the pigs, myocardial contrast enhancement with the 1.7 MHz real-time setting was compared with the 1:1 triggered setting at the same MI during the continuous infusion to determine whether there was evidence of differences in myocardial signal enhancement as a result of destruction. The wash out of the myocardial and left ventricular cavity contrast after infusion termination was also analyzed using Q laboratory measurements of digital intensity versus time.

All 3 settings (triggered 1.3/2.6 MHz harmonic, low MI 1.7 MHz power modulation imaging, and real time 1.7 MHz high MI imaging) were tested for both intravenous C3 and C3C4 droplet infusions. Before killing, the pigs had a balloon catheter advanced under fluoroscopy into the same location as the original left anterior descending artery (LAD) occlusion and inflated to reocclude the infarct vessel (if it was revascularized). No balloon was inserted if the vessel remained occluded at the original injury site. After this, a total of 65 mL of 3% Evans Blue (EB; 40 mL in the left main and 25 mL in the right coronary) was then injected through coronary catheters placed in the right and left main coronary arteries to define risk area. The pigs were subsequently euthanized, and postmortem triphenyl tetrazolium chloride (TTC) staining of infarct size and EB measurements of risk area were determined using planimetry.

Magnetic Resonance Imaging, Risk Area, and Postmortem TTC Staining

Magnetic resonance imaging scans were also performed at 48 hours after infarction just before droplet infusion studies using a 1.5 Tesla Magnet (Philips Achieva XL; Best, The Netherlands). Cine images using steady-state free precession were obtained in serial short axis views (slice thickness 8 cm, slice gap 2 cm, 45 ms temporal resolution, flip angle 60 degrees, TR 3 ms, TE 1.5 ms) to quantify left ventricular ejection fraction using the Philips View Forum workstation. After this, 0.15 mmol/kg of 0.2 mmol/kg dimeglumine gadopentetate (Magnevist; Bayer) was injected. At 10 min post injection, all short-axis views were examined using an inversion recovery turbo fast field echo/gradient recall ECG-triggered, segmented image collection for

Figure 1. The typical appearance of the C3 nanodroplets diluted to 15% in normal saline before infusion. Note the near complete absence of any microbubbles.
detection of extent of necrosis. Using a 16-segment model, segments exhibiting transmural (>50% thickness at end diastole) hyperenhancement and segments exhibiting any microvascular obstruction (persistent unenhanced portions within the hyperenhanced segments) were recorded using established criteria. All image interpretation and quantification were performed by an experienced level III trained cardiologist (Dr Sayyed) who was blinded to echocardiographic and postmortem staining results.

Statistical Comparisons
Because the presence or absence of myocardial contrast at high and low mechanical indices were obvious and consistent, comparisons of the presence or absence of myocardial contrast using the different imaging techniques used to activate the intravenously infused C3 versus C3C4 droplets were descriptive and not determined with contingency tables. When comparing myocardial contrast intensity between real time and triggered frame rates in the different animals (n=18 comparisons in 3 animals), a covariance structure which treats random variation because of the 3 pigs was performed, which then treats the paired data with a 2x2 unstructured covariance matrix. The average size of any visualized perfusion defect (at rest and during repeat LAD occlusion) with any of the imaging techniques was planimetered offline and compared with postmortem EB and TTC staining using a Spearman correlation with an exact P value to summarize the association. Statistical analyses were generated with SAS/STAT software, Version 9.4 (© 2002–2012 SAS Institute Inc).

Results
Activation Thresholds for Transthoracic Real-Time Imaging of Myocardial Contrast Enhancement
Figure 2 and Video I in the Data Supplement demonstrate the effect of MI on the presence of myocardial contrast enhancement achieved with a continuous intravenous C3 infusion. Note that at a specific MI (0.8), we begin to see myocardial and left ventricular cavity contrast which eventually encompasses the entire short axis at the 1.2 MI.

Acoustic Activation of C3 Versus C3C4 Droplet Infusions
A total of 8 pigs were examined with both the C3 and C3C4 droplet infusions. During the C3 infusion, consistent myocardial opacification and left ventricular cavity contrast were seen in all 8 pigs with the 1.3 MHz triggered (once every 1 and 4 cardiac cycles at end systole) harmonic imaging modality (Figure 3, example). No myocardial contrast and minimal left ventricular cavity contrast was seen with 1.7 MHz low MI power modulation imaging. However, in the 6 pigs in which real-time high MI harmonic imaging at 1.7 MHz was tested, myocardial contrast enhancement was observed in the uninfarcted myocardial microcirculation with excellent delineation of perfusion defects in 5 of 6 animals (Figure 4; Video II in the Data Supplement). This contrast persisted during and for ≤3 min after cessation of the 20% C3 infusion, and a time lapse quantitative measurements of contrast disappearance from the cavity and myocardium indicated that there was a linear disappearance of contrast from both regions (Figure 5), indicating that the created microbubbles were, for the most part, behaving as intravascular tracers and were not trapped within the microcirculation.

In the 3 pigs in which a triggered 1.7 MHz high MI end-systolic image (1:1 triggering) was compared with a real-time 1.7 MHz image at the same MI, a slight but highly significant increase in myocardial contrast intensity was observed (P<0.00001; n=18 comparisons in the 3 pigs). This would indicate that simultaneous generation and destruction of microbubbles is occurring in the microcirculation while in the real-time high MI mode (Figure 6).

In none of the 8 pigs was myocardial contrast achieved with the 20% C3C4 infusion.

![Figure 2. An example of C3 droplet activation during a continuous infusion of the droplets as mechanical index (MI) is increased at the 1.3 MHz frequency. Image frame rate was 30 Hz.](http://circimaging.ahajournals.org/)

![Figure 3. Triggered 1.3 MHz high mechanical index (MI) imaging during a C3 nanodroplet infusion in a pig with a small previous small inferoseptal myocardial infarction (arrows).](http://circimaging.ahajournals.org/)
Correlation With Infarct Size and Risk Area Assessments

At cardiac magnetic resonance imaging, the average ejection fraction of the pigs was 45±15% (range 29% to 74%). Median number of segments exhibiting transmural hyperenhancement was 4, with a range of 1 to 6.

During the C3 infusion with triggered end systolic 1:1 imaging at 1.3 MHz, delineation of perfusion defects was possible. This was also possible with the real-time high MI 1.7 MHz harmonic imaging in 5 of 6 pigs tested. Under resting conditions before reocclusion of the LAD, perfusion defect size (presumed infarct size) observed with 1:1 triggering at high MI 1.3 harmonic imaging and 1.7 MHz real-time high MI imaging averaged 1.86±1.29 cm², whereas TTC measurements of infarct size were 1.90±1.31 cm². There was a close correlation between perfusion defect size and TTC measurements ($r=0.95; P<0.001$; Figure 7, left) and with the number of transmurally infarcted segments measured at magnetic resonance imaging ($r=0.74; P=0.048$). Figure 8 depicts 2 examples of infarctions detected with real-time high MI imaging and corresponding TTC staining.

Assessment of perfusion defect size with the C3 infusion was possible during repeat LAD occlusion ischemia in 7 pigs. In this setting, the average perfusion defect size with both 1.3 MHz triggered and 1.7 MHz real-time high MI imaging correlated closely with unstained areas on postmortem EB staining ($r=0.97; P<0.001$; Figure 7, right).

Safety

During infusions of both agents, no changes in heart rate, systolic arterial pressure, or oxygen saturation were observed (Table). None of the animals exhibited premature ventricular contractions or other arrhythmias during the infusion of either C3 or C3C4. Postmortem TTC staining indicated no evidence of hemorrhage within the normal myocardium or within the infarct zones.

Discussion

This is the first article to demonstrate that intravenous nanodroplets can be acoustically activated with conventional trans-thoracic phased array transducers to detect both infarct size and risk area. Although these droplets were acoustically undetectable with conventional low MI techniques traditionally used to detect perfusion with microbubbles, they were consistently activated with triggered high MI harmonic techniques and, more importantly, visualized within the microcirculation with real-time high MI harmonic imaging techniques.

After acoustic activation, the C3 nanodroplets behaved similar to what has been described with larger-sized more concentrated intra-arterially injected microbubbles, in that they were resistant to high MI ultrasound destruction. It is unlikely that these microbubbles were trapped within the microcirculation because their disappearance after infusion termination correlated with disappearance of left ventricular cavity contrast. The 600- to 650- nm sized droplets would be expected to result in microbubbles that were at least 3 to 4 $\mu m$ in size and, perhaps, slightly larger because of inward diffusing dissolved nitrogen gas within the blood stream. Even at these sizes though, they would still be expected to pass freely through the myocardial capillaries while also being more resistant to destruction than smaller-sized perfluorocarbon microbubbles. Intravenously infused commercially available microbubbles within the capillaries would not be visualized at this high MI and frame rate because capillary blood replenishment with intravenously infused C3 microbubbles would not be expected at this frame speed. It is possible, therefore, that these created microbubbles were in a unique size range that was resistant...
to ultrasound-induced destruction but still capable of acting as free intravascular tracers. Other explanations for their resistance to destruction may be their resistance to shell buckling in response to diagnostic ultrasound pressures. High-speed optical imaging has shown that in some cases, microbubbles recently formed from vaporized liquid perfluorocarbons behave differently in response to diagnostic ultrasound when compared with commercially available microbubbles and do not exhibit shell buckling.\textsuperscript{15} Whether this renders them more resistant to destruction is not clear. One important caveat from this is that these created microbubbles cannot be used for the perfusion imaging techniques that take advantage of microbubble destruction to quantify myocardial blood flow.\textsuperscript{3}

Also, we did not observe any evidence of leaking of the microbubbles into infarcted segments. This may have been as a result of our ability to activate only the larger 600 nm C3 droplets that were confined to the intravascular spaces. According to the characterization results, the nanodroplets were polydisperse. It has been shown that the droplet activation threshold increases with decreasing droplet diameter.\textsuperscript{6} Therefore, it

Figure 6. A representative image and graphical display of the myocardial contrast enhancement achieved at 1:1 triggering at end systole versus real-time imaging at the same high mechanical index (1.2). The comparisons (n=19) were done in 3 separate pigs. There was a slight, but highly significant (P<0.0001) increase in signal intensity while in the triggering mode. This would indicate that some simultaneous generation and destruction of microbubbles is occurring in the microcirculation while in the real-time high mechanical index (MI). *P<0.0001 compared with real-time imaging.

Figure 7. Correlations between triphenyl tetrazolium chloride (TTC) derived infarct area (left) and averaged defect size from 1.3 MHz/2.6 MHz transthoracic triggered imaging and 1.7/3.4 MHz real-time harmonic imaging (r=0.95; P<0.001). During repeat left anterior descending occlusion, the Evans Blue (EB) unstained area (right) correlated closely with perfusion defect size using either the triggered 1:1 high mechanical index (MI) setting or real-time high MI setting. Data points are the same as pig number, and the correlations represent the average of measurements from the 1.3 MHz triggered data and 1.7 MHz real-time data for each pig. LAD indicates left anterior descending artery; and MCE, myocardial contrast echocardiography.
is possible that observed contrast enhancement was because of the activation of larger droplet content, and droplets small enough to cross damaged endothelial membranes may not have been activated at the pressures tested herein. This may explain the close correlation between contrast defect size with triggered high MI imaging and TTC measurements of infarct area as well as EB measurements of risk area.

C4 droplets, and droplets with 50% C4 content as used in the current study, seem to be more difficult to activate with the MI limits currently available with conventional diagnostic transthoracic transducers at the depths required for cardiac imaging in the pig and humans (≈4–10 cm from the anterior to posterior borders for transthoracic parasternal imaging as demonstrated in Figures 3–5). This is in agreement with in vitro studies that indicated that the droplet activation threshold increases with increasing molecular weight of the perfluorocarbon core.7

Limitations of Nanodroplet Formulations

A problem with the technique used to create droplets in the current study was the polydisperse nature of the formed droplets, ranging from 100 to 700 nm in diameter. It is possible that more monodisperse droplet distributions, designed for different clinical applications, could be created through techniques such as microfluidic particle generation16 or by optimizing the size distribution of the precursor bubble population.

The microbubbles created in this study were resistant to high MI destruction and, thus, cannot be used to perform targeted myocardial blood flow calculations similar to what is currently done with destruction replenishment curves using commercially available microbubbles.3 However, because the generated microbubbles still seem to function as free intravascular tracers, the targeted activation of left ventricular cavity droplets with a 3-dimensional high MI impulse after a bolus intravenous injection could be used as an input function to generate myocardial contrast time intensity curves to quantitatively assess transit rates that correlate with myocardial blood flow.17 Further work is needed to assess the feasibility of such methods.

Clinical Implications/Future Directions

All infusions of the nanodroplets resulted in no changes in myocardial function across a wide range of ejection fractions and no changes in hemodynamics, oxygen saturation, or damage outside the infarct zones. Therefore, this study suggests that there is clinical potential for this technique for real-time high MI transthoracic perfusion imaging. Although C3 droplets have not been tested with transthoracic imaging in humans, these pigs were large animals (mean weight 64±6 kg) and their parasternal locations for left ventricular cavity were similar to that which is seen in humans. The mechanical indices that were required to activate the microbubbles and permit myocardial contrast enhancement in both the near and far field were well within Food and Drug Administration limits.

This targeted activation technique at a high MI may improve the dynamic range within which myocardial blood volume can be analyzed and quantified with contrast echocardiography. Additional studies are needed to determine

Table. Hemodynamic Changes After a C3 or C4 Infusion

<table>
<thead>
<tr>
<th>Agent</th>
<th>MAP</th>
<th>O2 Sat</th>
<th>HR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before</td>
<td>After</td>
<td>Before</td>
</tr>
<tr>
<td>C3 infusion</td>
<td>68.0</td>
<td>68.1</td>
<td>98.5</td>
</tr>
<tr>
<td>C3/C4 infusion</td>
<td>69.3</td>
<td>71.8</td>
<td>97.8</td>
</tr>
</tbody>
</table>

No significant changes were observed in any parameter. HR indicates hazard ratio; and MAP, mean arterial pressure.
whether more precise sizes of nanodroplets can be created that would allow a consistent size of microbubble to be produced. Activation of the smaller 100 to 200 nm droplets that cross defective endothelial borders into infarct zones may allow highlighting of the infarct zone in a manner currently seen with delayed enhancement imaging, but this still has not been demonstrated. Droplets of larger size like those activated in the current study may be used to better delineate myocardial contrast defects seen with infarction, as well as identify normal myocardial contrast enhancement within dysfunctional segments (ie, hibernating myocardium). Overall, the ability of intravenous droplets to bypass the lung filtering effect and permit targeted acoustic activation only to zones where myocardial contrast is needed may further improve the safety of ultrasound contrast imaging and allow higher quality imaging of myocardial blood volume in acute coronary syndromes.

Acknowledgments

We appreciate the assistance of Terry Matsunaga (University of Arizona) in the early development of perfluorocarbon agents. We thank Nazar Filonov and the Nanomedicines Characterization Core Facility at University of North Carolina for the use of nanoparticle sizing equipment. We thank Carol Gould for her administrative assistance in article preparation, as well as Elizabeth Stoltze and Gretchen Fry for their assistance in performing the additional animal experiments.

Sources of Funding

The study was supported in part by the Theodore Hubbard Foundation and National Institute of Health Biomedical Research Partnership Grant No R01 HL095868, as well as the National Institute of General Medical Sciences, Division of Training, Workforce Development, and Diversity under the Institutional Research and Academic Career Development Award, grant No K12-GM000678.

Disclosures

Dr Porter has equipment support from General Electric Global and Philips Healthcare. Dr Porter has grant support from Lantheus Medical, Astellas Pharma, GE Healthcare. Dr Porter is on the Speaker’s Bureau for Bracco. Dr Dayton has patents pending on the phase change contrast agent formulations used here. The other authors report no conflicts.

References


CLINICAL PERSPECTIVE

This study demonstrates the potential for transthoracic ultrasound to target both the activation and imaging of systemically administered acoustic droplets that are <1 μm in size. Consistent real-time visualization of myocardial contrast enhancement was possible at 1.3 and 1.7 MHz frequencies. This targeted acoustic activation of intravenous perfluorocarbon droplets has not been previously demonstrated. Because these droplets range in size from 50 to 600 nm and do not become microbubbles until acoustically activated, they could be used for prolonged periods of time after intravenous injection and could be used to accurately identify the transmural extent and size of infarction in real time at a high mechanical index.
Targeted Transthoracic Acoustic Activation of Systemically Administered Nanodroplets to Detect Myocardial Perfusion Abnormalities
Thomas R. Porter, Christopher Arena, Samer Sayyed, John Lof, Robin R. High, Feng Xie and Paul A. Dayton

Circ Cardiovasc Imaging, 2016;9:
doi: 10.1161/CIRCIMAGING.115.003770
Circulation: Cardiovascular Imaging is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2015 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-9651. Online ISSN: 1942-0080

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circimaging.ahajournals.org/content/9/1/e003770

Data Supplement (unedited) at:
http://circimaging.ahajournals.org/content/suppl/2015/12/28/CIRCIMAGING.115.003770.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Cardiovascular Imaging can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Cardiovascular Imaging is online at:
http://circimaging.ahajournals.org//subscriptions/
VIDEO 1. Demonstration of transthoracic acoustic activation in real time using the 1.3 MHz center frequency and harmonic imaging at mechanical indices ranging from 0.2 up to 1.2. Only at the 1.2 mechanical index do we see activation in both the near (anterior) and far (inferior) segments.

VIDEO 2. Demonstration of acoustic activation in real time detecting the risk area during acute left anterior descending artery occlusion.